The US market for IVDs will exhibit moderate growth through 2027, driven by the aging US population and the shift toward value-based health care, which will fuel uptake of newer tests with improved diagnostic accuracy and reduced turnaround time.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IVDs in the US across a 10-year period.
The use of MDx tests will expand rapidly over the forecast period.
Which MDx tests will experience the highest growth throughout the forecast period?
How will adoption of MDx tests affect the other test segments in the IVD market?
The PAMA reimbursement revision will promote widespread pricing pressures and increasing laboratory consolidation in the US.
How must vendors adjust their strategies to adapt to this trend?
How will the growth prospects of the market be affected?
How will test volumes between the different facility types be affected?
The IVD competitive landscape consists of large MNCs as well as smaller niche competitors specializing in specific segments and diseases.
Which companies were leading the IVD market in 2018?
How do strategies differ between MNCs and smaller companies in this space?
What are the key purchasing criteria laboratories consider when selecting an IVD manufacturer?
- In Vitro Diagnostics - Market Insights - United States
Author(s): Benjamin Li, BBA
Benjamin Li is a team lead within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, with extensive knowledge in healthcare IT, women's health imaging, urology, large-joint reconstruction, spinal implants, and dental implants. Benjamin holds a Bachelor's degree in Business Administration from the Schulich School of Business, with a certificate in Managing International Trade and Investment.